Tags : Ripretinib

Deciphera Reports the US FDA’s Acceptance of NDA and Priority

Shots: The NDA submission is based on P-III INVICTUS study assessing ripretinib vs PBO in 129 patients in a ratio (2:1) with advanced GIST, prior treated with at least imatinib, sunitinib, and regorafenib The P-III INVICTUS study resulted in meeting its 1EPs i.e. improvement in PFS in patients with 4L/4L+ GIST as assessed by RECIST version […]Read More